Teigland Christie, Pulungan Zulkarnain, Bruhn David, Hwang Steve
Inovalon Insights, Bowie, Maryland, USA.
Otsuka America Pharmaceutical, Inc., Princeton, New Jersey, USA.
J Health Econ Outcomes Res. 2024 Oct 29;11(2):118-124. doi: 10.36469/001c.124455. eCollection 2024.
Agitation in Alzheimer dementia is common, but the associated healthcare burden remains unclear. This retrospective analysis evaluated baseline characteristics, healthcare resource utilization, and costs among patients with agitation in Alzheimer dementia and those without agitation in Alzheimer dementia. Medicare beneficiaries from 100% of the Medicare Fee-for-Service claims database (2009-2016) with 2 or more claims 30 or more days apart for both Alzheimer's disease and dementia and continuous enrollment with medical/pharmacy coverage for 6 months before and 12 months after the index diagnosis were included. Patients with agitation in Alzheimer dementia were identified by 2 or more claims 14 or more days apart using codes based on the provisional International Psychogeriatric Association agitation definition. Patients with severe psychiatric disorders were excluded. Two cohorts of patients (with and without agitation) were then defined, and patient characteristics, healthcare resource utilization, and costs were compared in a descriptive exploratory analysis. Of 2 684 704 Fee-for-Service patients with Alzheimer dementia, 769 141 met all inclusion criteria; among these, 281 042 (36.5%) had agitation. The mean age in patients with and without agitation in Alzheimer dementia was 83 years. Most patients in both groups were female, but the proportion of males was slightly higher in the agitation in Alzheimer dementia group (30.3% vs 28.2%, respectively). Patients with agitation in Alzheimer dementia were more likely than those without agitation in Alzheimer dementia to have lower socioeconomic status (dual eligibility for Medicaid, 45.0% vs 41.7%, respectively) or be disabled (10.5% vs 9.4%). Overall, healthcare costs were higher in the agitation in Alzheimer dementia population compared with those without agitation in Alzheimer dementia (mean cost PPPY, 30 121, respectively), with the largest differences observed in inpatient and post-acute care costs. These exploratory findings underscore the substantial economic burden of agitation in Alzheimer dementia and highlight the need for treatment options for the agitation in Alzheimer dementia population to improve associated health outcomes.
阿尔茨海默病性痴呆中的激越很常见,但与之相关的医疗负担仍不明确。这项回顾性分析评估了阿尔茨海默病性痴呆伴有激越和不伴有激越患者的基线特征、医疗资源利用情况及费用。纳入了来自100%医疗保险按服务付费索赔数据库(2009 - 2016年)的医疗保险受益人,他们患有阿尔茨海默病和痴呆,且相隔30天或更长时间有2次或更多次索赔,并且在索引诊断前6个月和诊断后12个月连续享有医疗/药房保险。阿尔茨海默病性痴呆伴有激越的患者通过基于国际老年精神病学协会临时激越定义的编码,相隔14天或更长时间有2次或更多次索赔来确定。排除患有严重精神疾病的患者。然后定义了两组患者(伴有激越和不伴有激越),并在描述性探索性分析中比较了患者特征、医疗资源利用情况及费用。在2684704名按服务付费的阿尔茨海默病性痴呆患者中,769141名符合所有纳入标准;其中,281042名(36.5%)有激越。阿尔茨海默病性痴呆伴有激越和不伴有激越患者的平均年龄均为83岁。两组中的大多数患者为女性,但阿尔茨海默病性痴呆伴有激越组中的男性比例略高(分别为30.3%和28.2%)。与阿尔茨海默病性痴呆不伴有激越的患者相比,伴有激越的患者更有可能社会经济地位较低(同时符合医疗补助双重资格,分别为45.0%和41.7%)或有残疾(10.5%和9.4%)。总体而言,与阿尔茨海默病性痴呆不伴有激越的人群相比,伴有激越人群的医疗费用更高(平均费用每年购买力平价分别为30121美元),住院和急性后期护理费用差异最大。这些探索性研究结果强调了阿尔茨海默病性痴呆中激越的巨大经济负担,并突出了需要为阿尔茨海默病性痴呆伴有激越人群提供治疗选择以改善相关健康结局的必要性。